During a live event, Nathan M. Denlinger, DO, MS, discussed the PILOT and ALYCANTE trials of CAR T-cell therapy in transplant ...

In recent years, the therapeutic landscape for hematological malignancies has undergone a profound transformation, driven by ...

CellProthera says it chose CELLforCURE by SEQENS as its CDMO for the quality of its infrastructure, equipment, and expertise of its team.

RxDx assay as a companion diagnostic to identify c-Met protein expression in non-squamous NSCLC patients eligible for treatment with Emrelis.

An unprecedented international effort to decode how cells manage the transport of chemical substances has culminated in four groundbreaking studies This decade-long project provides the first ...